Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

Completed · Phase 3

Conditions studied: Psoriatic Arthritis

In brief

The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in treatment of moderate to severely active psoriatic arthritis

Key facts

Study ID

NCT00195689

Run by

Abbott

People needed

400

Starts

2003-08-01

Last updated by the study team

2007-08-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject completed study M02-518 or M02-570

You may not qualify if…

• Subject prematurely discontinued study M02-518 or M02-570
• Female subject who is pregnant or breast-feeding or considering becoming pregnant
• Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study

Where it is running

• Global Medical Information-Abbott Laboratories — Abbott Park, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.